Adamas Reports First Quarter 2020 Financial Results
07. Mai 2020 16:03 ET
|
Adamas Pharmaceuticals, Inc.
First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019 EMERYVILLE,...
Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
27. April 2020 16:03 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May...
Adamas Announces New Employment Inducement Grant
10. April 2020 16:06 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven...
Adamas Announces New Employment Inducement Grant
06. März 2020 16:39 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new...
Adamas Reports Fourth Quarter and Full Year 2019 Financial Results
25. Februar 2020 16:03 ET
|
Adamas Pharmaceuticals, Inc.
- Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018;total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI® product sales of $16.3...
Adamas to Present at Upcoming Healthcare Conferences
20. Februar 2020 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020
19. Februar 2020 16:02 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,...
Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
13. Februar 2020 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease
11. Februar 2020 16:15 ET
|
Adamas Pharmaceuticals, Inc.
- Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease - Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF...
Adamas Announces New Employment Inducement Grant
10. Januar 2020 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...